Stable Istotope Labelled Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade

Reference: PX-TA1297-SIL-1MG
Product nameStable Istotope Labelled Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade
SourceCAS 1000676-41-4
SpeciesHomo sapiens
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsBMS-986015,IPH2102
ReferencePX-TA1297-SIL
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeHuman IgG1
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody

Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below